Summary

Other Scenarios:

Buyer: Novo Nordisk A/S (ADR) (NVO) Last Price: 134.50 Market Cap.: 63.55B
Target: Amylin Pharmaceuticals, Inc. (AMLN) Last Price: 17.17 Market Cap.: 2.50B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
Healthcare 737
Biopharmaceuticals 336
Digestive System   4
Phase I/Phase II Clinical Stage Products   0
Endocrinology/Metabolism 11
Diabetes 4
General Hormone Treatments   0
Hypoglycemia   0
Phase I/Phase II Clinical Stage Products 0
Pituitary Gland Disorders 0
Reproductive Disorders   0
Hematology   6
Hemophilia   0
Phase I/Phase II Clinical Stage Products   0
Serum Factor Disorders   1
Immunology   2
Phase I/Phase II Clinical Stage Products   0
Musculoskeletal System   3
Phase I/Phase II Clinical Stage Products   0
Skeletal Disorders   0
Neurology   29
Phase I/Phase II Clinical Stage Products   0
Obstetrics/Gynecology   2
Female Genital Disorders   0
Oncology   63
Phase I/Phase II Clinical Stage Products   0
Research/Preclinical Stage Products   0
Surgery   3
General   1
Phase I/Phase II Clinical Stage Products   0
Urology   2
Phase I/Phase II Clinical Stage Products   0
Weight Management 1
Obesity   1
Phase I/Phase II Clinical Stage Products   0
Research/Preclinical Stage Products   0
Medical Devices   176
Drug Delivery   7
Percutaneous (Subcutaneous/Intramuscular/Intravenous)   2

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 51)
  • Liraglutide (Human GLP-1 Analogue)
  • NN5401 (Next-Generation Insulin Analogue)
  • DegludecPlus (Insulin Degludec/Insulin Aspart)
  • NN9068
Target (Total: 6)
  • Symlin (Pramlintide Acetate)
  • Bydureon (Exenatide Extended-Release For Injectable Suspension)
  • Byetta (Exenatide)
Buyer
  • NovoSeven (Recombinant Coagulation Factor VIIa)
  • Vagifem (Estradiol Vaginal Tablets, USP)
  • GlucaGen (Recombinant Glucagon)
  • Oral Glucagon-Like Peptide-1 (GLP-1)
Target
  • Pramlintide/Metreleptin
  • Byetta (Exenatide)
  • Metreleptin
  • Bydureon (Exenatide Extended-Release For Injectable Suspension)

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 8)
  • Crucell N.V. (ADR) (CRXLY)
  • Emisphere Technologies, Inc. (EMIS)
  • Neose Technologies Inc (NTEC.5)
  • Addtech AB (ADDT.B:SE)
Target (Total: 13)
  • Alexandria Real Estate Equities, Inc. (ARE)
  • Amgen, Inc. (AMGN)
  • Baxter International Inc. (BAX)
  • Covidien plc (COV)
Buyer (Total: 2)
  • Amicus Therapeutics, Inc. (FOLD)
  • Government - United States
Target (Total: 6)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • Medco Health Solutions Inc. (MHS)
  • AmerisourceBergen Corp. (ABC)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 31,549 1,400
Revenue Per Employee 416,260.5 452,855.0
Total Revenue 18,120.0 164.9
Total Expenses 12,039.0 594.7
Other Revenue n/a n/a
Cost of Revenue 3,122.0 12.3
SG&A Expense 6,165.0 78.3
Research & Development 2,752.0 27.7
Other Operating Expense n/a 43.1
Operating Income 6,081.0 -429.8
Unusual Income n/a 433.3
LT Debt to Capital 1.32 110.83
Fwd P/E 22.28 -11.22
Fwd P/Rev 4.79 3.68
Book Value 37,448.0 -138.7
Curr Portion of LTD/Cap Lease 351.0 n/a

Individual Company Summary

Focused

Buyer

Focused (): Healthcare > Biopharmaceuticals > Endocrinology/Metabolism > Diabetes

Target

Focused (): Healthcare > Biopharmaceuticals > Endocrinology/Metabolism > Diabetes

Business Description

Buyer

Novo Nordisk A/S is a healthcare company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition, it is engaged in areas, such as haemophilia, growth hormone therapy and hormone replacement therapy. It manufactures and markets pharmaceutical products and services to patients, the medical profession and society. It operates in two segments: diabetes care and biopharmaceuticals. It operates in four geographical regions North America: the United States and Canada; Europe: the European Union, EFTA, Albania, Bosnia-Herzegovina, Croatia, Macedonia, Serbia, Montenegro and Kosovo; Japan and Korea, and International Operations: all other countries, including China. Its products include Victoza, NovoNorm/Prandin/PrandiMet, NovoSeven and Norditropin.

Target

Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Its wholly owned subsidiaries are Amylin Ohio, LLC, and Amylin Investments, LLC. It is marketing two medicines to treat diabetes, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection and it is seeking approval for BYDUREON (exenatide extended-release for injectable suspension), an investigational sustained-release medication for type-II diabetes, which is administered only once a week. It is focused on making prudent investment decisions based on positive clinical data to advance its obesity program, including the development of pramlintide/ metreleptin, a combination therapy for the treatment of obesity, which the Company and its obesity partner, Takeda Pharmaceutical Company Limited (Takeda), is advancing toward phase-III development.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 81.42 92.57
Operating Margin % 60.48 -75.53
Quick Ratio 1.33 1.99
Current Ratio 1.91 1.42
Coverage Ratio n/a n/a
Total Assets 64,698.0 1,870.2
Return on Equity % 112.07 n/a
Return on Assets % 64.87 -116.22
Cash+ ST Inv. Per Share 31.16 3.71
Total Debt 853.0 1,633.0
Total Debt to Equity % 2.28 0
Total Debt to Tangible Equity % 2.37 n/a
Debt to Asset % 1.32 87.32

Product Summary

Sector Buyer Target
Healthcare
Biopharmaceuticals
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
  
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Weight Management
The Weight Management Subsectors includes therapeutics that treat and manage weight disorders.
Medical Devices  
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
Healthcare
Biopharmaceuticals
Digestive System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • NovoSeven (Recombinant Coagulation Factor VIIa)
  
Endocrinology/Metabolism
Diabetes
Insulin Dependent Diabetes Mellitus (IDDM)/Type 1 Diabetes
Insulin Therapy
Adjunctive
Therapeutics that treat Insulin Dependent Diabetes Mellitus by insulin or insulin-like supplements.

Buyer Products:

  • NN5401 (Next-Generation Insulin Analogue)
  • DegludecPlus (Insulin Degludec/Insulin Aspart)
  • NN9068
  • Degludec (Insulin Degludec)

Target Products:

  • Symlin (Pramlintide Acetate)
Human Analogs
Insulin supplements that resemble natural human insulin.

Buyer Products:

  • Levemir (Insulin Detemir)
  • NovoLog (Insulin Aspart (rDNA Origin))
  • NovoLog Mix 70/30 (Insulin Aspart)
  • NovoMix 50 (Insulin Aspart Mixture)
  • NovoMix 70 (Insulin Aspart Mixture)
  
Recombinant Human
Therapeutics that are derived from human genes.

Buyer Products:

  • Novolin R (Regular Insulin)
  • Novolin N (Isophane Insulin Suspension)
  • Novolin 70/30 (Isophane/Regular Insulin)
  
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes
Biguanides/Insulin Stimulating Agents
Therapeutics that control high blood sugar by stimulating the release of insulin as well as decreasing the production of glucose in the liver.

Buyer Products:

  • PrandiMet (Repaglinide/Metformin Fixed Combo)
  
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 Receptor Agonists)
Therapeutics that treat non-insulin dependent diabetes by stimulating the Glucagon-Like Peptide (GLP) receptor. GLP regulates gastric emptying, insulin secretion, food intake, and glucagon secretion.

Buyer Products:

  • Victoza (Liraglutide)

Target Products:

  • Bydureon (Exenatide Extended-Release For Injectable Suspension)
  • Byetta (Exenatide)
Insulin Stimulating Agents (Non-Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.

Buyer Products:

  • Prandin (Repaglinide)
  
Insulin Therapy
Adjunctive
Therapeutics that aids in, but not essential, to insulin therapy for the treatment of diabetes.

Target Products:

  • Symlin (Pramlintide Acetate)
  
Human Analogs
Insulin supplements that resemble natural human insulin.

Buyer Products:

  • NovoLog (Insulin Aspart (rDNA Origin))
  • NovoLog Mix 70/30 (Insulin Aspart)
  • Levemir (Insulin Detemir)
  • NovoMix 50 (Insulin Aspart Mixture)
  • NovoMix 70 (Insulin Aspart Mixture)
  
Recombinant Human
Therapeutics that are derived from human genes.

Buyer Products:

  • Novolin N (Isophane Insulin Suspension)
  • Novolin R (Regular Insulin)
  • Novolin 70/30 (Isophane/Regular Insulin)
  
Partial Fatty Acid Oxidation Inhibitors (pFOX Inhibitors)
Therapeutics that treat non-insulin dependent diabetes by shifting energy production away from fatty acid oxidation toward glucose oxidation, leading to a reduction in HbA1C.

Buyer Products:

  • NN5401 (Next-Generation Insulin Analogue)
  
General Hormone Treatments  
Estrogens
Therapeutics that treat hormonal disorders by providing estrogen.

Buyer Products:

  • Vagifem (Estradiol Vaginal Tablets, USP)
  
Hypoglycemia  
Gluconeogenic Agents/Glycogenolytic Agents
Therapeutics that treat hypoglycemia by enabling the release of glucose from the liver.

Buyer Products:

  • GlucaGen (Recombinant Glucagon)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Oral Glucagon-Like Peptide-1 (GLP-1)
  • Long-Acting Growth Hormone
  • NN9535 (Once-Weekly GLP-1 Analog)
  • Victoza (Liraglutide)
  • NN9924 (Oral GLP-1)
  • NN1218
  • NN9068
  • NN1952 (Oral Insulin Analogue)

Target Products:

  • Pramlintide/Metreleptin
  • Byetta (Exenatide)
Pituitary Gland Disorders
Lipodystrophy  
Adipose Hormones
Therapeutics that treat lipodystrophy by providing a hormone which is synthesized by adipose cells and is responsible for regulating appetite and energy expenditure. Leptin is one of the major hormones belonging to this family of adipose hormones.

Target Products:

  • Metreleptin
  
Severe Short Stature  
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.

Buyer Products:

  • Norditropin/Norditropin FlexPro (r-Somatropin)
  
Turner`s Syndrome  
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.

Buyer Products:

  • Norditropin/Norditropin FlexPro (r-Somatropin)
  
Reproductive Disorders  
Menopause  
Estrogens
Therapeutics that are female sex hormones.

Buyer Products:

  • Vagifem (Estradiol Vaginal Tablets, USP)
  
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.

Buyer Products:

  • Activella (Estradiol/Norethindrone Acetate)
  
Hematology  
Hemophilia  
Factor XIII Deficiency
Therapeutics that treat a form of hemophilia caused by a hereditary deficiency in blood coagulation Factor XIII.

Buyer Products:

  • rFactor XIII
  
Hemophilia A  
Clotting Agents
Therapeutics that aid in blood coagulation.

Buyer Products:

  • NN7008 (Recombinant Factor VIII)
  • NovoSeven (Recombinant Coagulation Factor VIIa)
  
Hemophilia B  
Clotting Agents
Therapeutics that assist in blood coagulation.

Buyer Products:

  • NovoSeven (Recombinant Coagulation Factor VIIa)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • NN1731 (Recombinant Factor VII Short-Acting Analog)
  • NN7128 (GlycoPEGylated Factor VIIa)
  • NN7415 (Factor Pathway Inhibitor)
  • NN7088 (Factor VIII Derivative)
  • NN7129 (Factor VIIa Derivative)
  • NN7999 (Factor IX Derivative)
  • rFVIIa Analog (Recombinant Factor VII Long-Acting Analog)
  • Pegylated Recombinant Factor IX
  
Serum Factor Disorders  
Hypoglycemia  
Gluconeogenic Agents/Glycogenolytic Agents
Therapeutics that treat low blood sugar by promoting the breakdown of glycogen into glucose in the liver as well as the synthesis of glucose from non-carbohydrate precursors.

Buyer Products:

  • GlucaGen (Recombinant Glucagon)
  
Immunology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Anti-NKG2d (Recombinant Monoclonal Antibody)
  • Anti-c5aR
  • Anti-IL20
  • IL-21 mAb
  
Musculoskeletal System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Anti-NKG2d (Recombinant Monoclonal Antibody)
  • Anti-c5aR
  • Anti-IL20
  • IL-21 mAb
  
Skeletal Disorders  
Bone Disorders  
Osteoporosis  
Hormonal Treatments  
Estrogens/Progestins
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.

Buyer Products:

  • Activella (Estradiol/Norethindrone Acetate)
  
Neurology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • NovoSeven (Recombinant Coagulation Factor VIIa)
  
Obstetrics/Gynecology  
Female Genital Disorders  
Vulvovaginal  
Atrophy  
Hormonal Treatments  
Estrogens/Progestins
Therapeutics that treat disorders characterized by thinning of the vaginal walls with a combination of the female sex hormones estrogen and progestin.

Buyer Products:

  • Activella (Estradiol/Norethindrone Acetate)
  
Oncology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • Anti-KIR (IgG4 Monoclonal Antibody)
  • Interleukin 21 (IL-21)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • Interleukin 21 (IL-21)
  
Surgery  
General  
Complications  
Hemorrhage  
Coagulating Agents (Coagulants)
Therapeutics that treat bleeding during a surgical procedure by promoting blood clotting.

Buyer Products:

  • NovoSeven (Recombinant Coagulation Factor VIIa)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of surgical complications in early stages of clinical research where human subject is involved.

Buyer Products:

  • NN1810 (Recombinant Factor XIII)
  • NovoSeven (Recombinant Coagulation Factor VIIa)
  
Urology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Norditropin/Norditropin FlexPro (r-Somatropin)
  
Weight Management
Obesity  
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 Receptor Agonists)
Therapeutics that treat obesity by stimulating the Glucagon-Like Peptide (GLP) receptor. GLP regulates gastric emptying, insulin secretion, food intake, and glucagon secretion.

Buyer Products:

  • Liraglutide (Human GLP-1 Analogue)
  • Victoza (Liraglutide)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Pramlintide/Metreleptin
  • Bydureon (Exenatide Extended-Release For Injectable Suspension)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in very early stages of research where no human subject is involved.

Target Products:

  • AC165198 (Peptide Hybrid)
  
Medical Devices  
Drug Delivery  
Percutaneous (Subcutaneous/Intramuscular/Intravenous)  
Automatic Injectors
Pen-shaped medical devices used to contain and deliver liquid medications to a specified needle depth with a press of a button.

Buyer Products:

  • Norditropin NordiFlex/NordiFlex PenMate
  • Levemir Flexpen
  • NovoLog FlexPen/Novolog MIX 70/30 FlexPen
  • NordiPen/NordiPenMate Systems
  • Novolin InnoLet
  • NovoPen Delivery System Series
  
Needleless  
Disposable  
Hypodermic
Disposable needles for use below the skin.

Buyer Products:

  • NovoFine Insulin Series
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Rel. Revenue % Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Merck & Co., Inc. n/a 116,793.014 18.78 10.04 2.43 2.49 n/a
GlaxoSmithKline plc (ADR) n/a 113,660.167 10.19 11.73 3.15 2.52 n/a
Sanofi n/a 100,449.816 19.70 9.79 2.35 2.20 n/a
Bristol Myers Squibb Co. n/a 54,410.777 14.72 16.32 2.56 3.02 n/a
Eli Lilly & Co. n/a 45,508.755 10.45 12.43 1.87 2.04 n/a
VIVUS, Inc. n/a 1,096.979 n/a -26.60 n/a 21.36 7.29
Orexigen Therapeutics, Inc. n/a 145.697 n/a -3.53 32.97 36.12 9.25
Generex Biotechnology Corporation n/a 45.834 n/a n/a 365.68 n/a n/a
Harbor BioSciences, Inc. n/a n/a n/a n/a n/a n/a n/a
Takeda Yakuhin Kogyo KK n/a n/a n/a n/a n/a n/a n/a
Buyer
  Merck & Co., Inc. n/a 116,793.014 18.78 10.04 2.43 2.49 n/a
GlaxoSmithKline plc (ADR) n/a 113,660.167 10.19 11.73 3.15 2.52 n/a
Target
  Pfizer Inc. n/a 164,234.752 11.51 9.35 1.63 2.66 n/a
Novartis AG (ADR) n/a 153,452.869 16.55 10.21 2.58 2.65 38.10
Roche Holding AG n/a 152,639.104 26.49 11.90 2.23 3.24 n/a
Merck & Co., Inc. n/a 116,793.014 18.78 10.04 2.43 2.49 n/a
GlaxoSmithKline plc (ADR) n/a 113,660.167 10.19 11.73 3.15 2.52 n/a
Sanofi n/a 100,449.816 19.70 9.79 2.35 2.20 n/a
Abbott Laboratories n/a 85,782.958 18.11 11.01 2.21 2.15 n/a
Novo Nordisk A/S (ADR) n/a 63,552.972 10.16 22.28 1.56 4.79 1.77
AstraZeneca plc (ADR) n/a 63,542.111 6.65 7.65 1.89 2.14 26.43
Bristol Myers Squibb Co. n/a 54,410.777 14.72 16.32 2.56 3.02 n/a
Eli Lilly & Co. n/a 45,508.755 10.45 12.43 1.87 2.04 n/a
VIVUS, Inc. n/a 1,096.979 n/a -26.60 n/a 21.36 7.29
Raptor Pharmaceuticals Corp. n/a 511.375 n/a -40.84 n/a 96.57 4,297.27

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Rel. Revenue % Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Ypsomed Holding AG n/a n/a n/a n/a n/a n/a n/a
Buyer
  Crucell N.V. (ADR) n/a 2,252.813 n/a n/a 3.38 n/a 2.57
Emisphere Technologies, Inc. n/a 17.596 n/a -1.88 731.69 21.57 n/a
Neose Technologies Inc n/a 0.599 n/a n/a 0.06 n/a n/a
Addtech AB n/a n/a n/a n/a n/a n/a n/a
Companhia de Saneamento de Minas Gerais n/a n/a n/a n/a n/a n/a n/a
Ypsomed Holding AG n/a n/a n/a n/a n/a n/a n/a
Nolato AB n/a n/a n/a n/a n/a n/a n/a
Gerresheimer AG n/a n/a n/a n/a n/a n/a n/a
Target
  Alexandria Real Estate Equities, Inc. 1.40% 4,817.033 23.55 16.00 6.90 8.09 1.43
Amgen, Inc. n/a 62,246.797 17.95 11.21 3.99 3.80 13.26
Baxter International Inc. n/a 32,299.699 14.72 12.51 2.32 2.28 n/a
Covidien plc n/a 25,510.910 13.41 12.17 2.18 2.17 n/a
W.P. Carey & Co LLC n/a 1,762.127 10.40 13.34 4.07 16.82 3.10
Pacira Pharmaceuticals Inc n/a 177.846 n/a -5.81 13.03 5.75 26.66
Marina Biotech Inc n/a n/a n/a n/a n/a n/a n/a
Alkermes PLC n/a n/a n/a -28.86 n/a n/a n/a
Lonza Group AG n/a n/a n/a 10.80 n/a n/a n/a
BACHEM HOLDING LTD n/a n/a n/a n/a n/a n/a n/a
Wockhardt Ltd n/a n/a n/a n/a n/a n/a n/a
Ypsomed Holding AG n/a n/a n/a n/a n/a n/a n/a
Vetter Pharma-Fertigung GmbH & Co. KG n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Rel. Revenue % Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Amicus Therapeutics, Inc. n/a 231.823 n/a -6.85 13.86 5.53 n/a
Government - United States n/a n/a n/a n/a n/a n/a n/a
Target
  McKesson Corporation 36.00% 20,034.392 20.29 12.92 0.17 0.17 n/a
Cardinal Health, Inc. 35.00% 14,682.563 15.60 13.25 0.14 0.14 8.72
Medco Health Solutions Inc. 14.00% 23,448.634 17.31 13.35 0.34 0.40 n/a
AmerisourceBergen Corp. 10.00% 10,393.305 15.27 13.87 0.13 0.13 3.58
Eli Lilly & Co. n/a 45,508.755 10.45 12.43 1.87 2.04 n/a
Takeda Yakuhin Kogyo KK n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Rel. Revenue % Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Pacira Pharmaceuticals Inc n/a 177.846 n/a -5.81 13.03 5.75 26.66
Ypsomed Holding AG n/a n/a n/a n/a n/a n/a n/a
Buyer
  Pfizer Inc. n/a 164,234.752 11.51 9.35 1.63 2.66 n/a
UnitedHealth Group Inc. n/a 57,380.798 11.29 11.08 0.56 0.53 2.03
Bristol Myers Squibb Co. n/a 54,410.777 14.72 16.32 2.56 3.02 n/a
Crucell N.V. (ADR) n/a 2,252.813 n/a n/a 3.38 n/a 2.57
Amicus Therapeutics, Inc. n/a 231.823 n/a -6.85 13.86 5.53 n/a
Pacira Pharmaceuticals Inc n/a 177.846 n/a -5.81 13.03 5.75 26.66
Target
  Amgen, Inc. n/a 62,246.797 17.95 11.21 3.99 3.80 13.26
Eli Lilly & Co. n/a 45,508.755 10.45 12.43 1.87 2.04 n/a
Teva Pharmaceutical Industries Ltd (ADR) n/a 41,528.227 13.87 7.99 2.44 1.92 50.15
Baxter International Inc. n/a 32,299.699 14.72 12.51 2.32 2.28 n/a
Covidien plc n/a 25,510.910 13.41 12.17 2.18 2.17 n/a
Sharp Corporation (ADR) n/a 7,608.295 n/a -4.10 0.01 0.20 0.01
Pacira Pharmaceuticals Inc n/a 177.846 n/a -5.81 13.03 5.75 26.66
Wockhardt Ltd n/a n/a n/a n/a n/a n/a n/a
Marina Biotech Inc n/a n/a n/a n/a n/a n/a n/a
Biocon Ltd n/a n/a n/a n/a n/a n/a n/a
Vetter Pharma-Fertigung GmbH & Co. KG n/a n/a n/a n/a n/a n/a n/a
Lonza Group AG n/a n/a n/a 10.80 n/a n/a n/a
Alkermes PLC n/a n/a n/a -28.86 n/a n/a n/a
Ypsomed Holding AG n/a n/a n/a n/a n/a n/a n/a
Juvenile Diabetes Research Foundation International n/a n/a n/a n/a n/a n/a n/a
Takeda Yakuhin Kogyo KK n/a n/a n/a n/a n/a n/a n/a
BACHEM HOLDING LTD n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 40,838.9 650.7 41,489.6
Other Revenue n/a n/a n/a
Total Revenue 40,838.9 650.7 41,489.6
Cost of Revenue 7,586.7 48.4 7,635.1
SG&A Expense 13,559.3 271.2 13,830.6
Depreciation & Amortization n/a n/a n/a
Research & Development 5,915.5 161.2 6,076.8
Interest Expense n/a n/a n/a
Other Operating Expense n/a 222.5 222.5
Unusual Expense (Income) n/a 438.8 438.8
Total Expenses 16,139.6 1,142.1 17,281.7
Operating Income 24,699.4 -491.5 24,207.9
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng -5.7 -46.5 -52.3
Other, Net n/a n/a n/a
Income Before Taxes 13,347.6 -543.4 12,804.2
Income Taxes 2,855.5 n/a 2,855.5
Income After Taxes 10,492.1 -543.4 9,948.7
Net Income - Excl. Xord. Items 10,492.1 -543.4 9,948.7
Net Income - Incl. Xord. Items 10,492.1 -543.4 9,948.7
Income Avail. to Common 10,492.1 -543.4 9,948.7
Share Items
Basic Avg. Shares Outstanding 557.3 146.3 703.6
Basic EPS - Excl. Xord. Items 11.22 -3.72 14.14
Basic EPS - Incl. Xord. Items 18.67 -3.72 14.14
Full Dilution Adjustment n/a n/a n/a
Fully Diluted Shares Outstanding 561.8 146.3 708.0
F.D. EPS - Excl. Xord. Items 18.52 -3.72 14.05
F.D. EPS - Incl. Xord. Items 11.13 -3.72 14.05
Balance Sheet
Assets
Cash and Equivalents 13,408.0 204.1 13,612.1
ST Investments 4,094.0 338.4 4,432.4
Accounts Receivable 10,232.0 45.5 10,277.5
Inventory 9,433.0 112.0 9,545.0
Prepayments and Advances n/a 15.7 15.7
Other Current Assets 2,424.0 59.7 2,483.7
Current Assets 39,591.0 421.2 40,012.2
Accum D&A n/a n/a n/a
PPE, Net 20,931.0 831.2 21,762.2
Goodwill & Intangibles 1,489.0 601.5 2,090.5
Long Term Investments 39.0 n/a 39.0
Other Assets n/a n/a n/a
Other LT Assets 2,648.0 16.3 2,664.3
Total Assets 64,698.0 1,870.2 66,568.2
Liabilities
Accounts Payable 3,291.0 21.5 3,312.5
Payable/Accrued n/a n/a n/a
Accrued Expenses n/a 139.1 139.1
ST Debt n/a 12.7 12.7
Curr Port of LTD & Cap Lease Oblg 351.0 200.0 551.0
Other (Current) Liabilities 17,137.0 296.0 17,433.0
Current Liab. 20,779.0 296.0 21,075.0
LT Debt 502.0 1,420.3 1,922.3
Total LT Debt 502.0 1,420.3 1,922.3
Deferred Taxes 3,206.0 n/a 3,206.0
Other LT Liab. 2,763.0 292.6 3,055.6
Total Liabilities 27,250.0 2,008.9 29,258.9
Shareholders Equity
Common Stock 580.0 0.1 580.1
Additional Paid in Capital n/a 2,496.3 2,496.3
Retained Earnings 36,892.0 -2,182.1 34,709.9
Treasure Stock -24.0 n/a -24.0
Other Equity n/a -138.7 -138.7
Total Equity 37,448.0 -138.7 37,309.3
Total Liab. & Equity 64,698.0 1,870.2 66,568.2
Shares Outstanding 566.7 146.3 712.9
Cash Flow
Operating Cash Flow
CF Net Income 10,492.1 -81.9 10,410.2
CF Depreciation -1,151.6 36.9 -1,114.7
CF Deferred Taxes n/a n/a n/a
Other Non-Cash Items 2,073.9 45.4 2,119.3
Change in Working Capital 2,204.7 68.6 2,273.3
Total Cash From Operating Activities 13,619.1 69.0 13,688.1
Investing Cash Flow (not calculated)
Capital Expenditures -2,249.9 -38.8 -2,288.7
Other Investing Cash Flows -947.1 -60.6 -1,007.7
Total Cash From Investing Activities -3,197.0 -99.4 -3,296.4
Financing Cash Flow (not calculated)
Dividends Paid -1,134.0 n/a -1,134.0
Purchase Or Sale of Stock -7,958.5 8.3 -7,950.2
Purchase and Retirement of Debt -507.0 -200.0 -707.0
Other Financing Cash Flow n/a n/a n/a
Total Cash From Financing Activities -9,599.4 -26.7 -9,626.1
Exchange Rate Effects 12.6 n/a 12.6
Net Change in Cash 835.3 -57.1 778.1
Cash Taxes Paid 4,117.5 n/a 4,117.5
Cash Interest Paid 197.3 n/a 197.3